(4aR,8aS,9aR,10aS)-tetradecahydroanthracene | 1755-19-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: (4aR,8aS,9aR,10aS)-tetradecahydroanthracene
• 英文别名: trans-syn-trans-Perhydroanthracen；trans-cisoid-trans-perhydroanthracene；trans,syn,trans-Tetradecahydro-anthracen；trans-syn-trans-Perhydroanthracene；(4aR,8aS,9aR,10aS)-1,2,3,4,4a,5,6,7,8,8a,9,9a,10,10a-tetradecahydroanthracene
• CAS: 1755-19-7
• 化学式: C₁₄H₂₄
• 分子量: 192.345
• InChiKey: GVJFFQYXVOJXFI-KJGYPYNMSA-N

物化性质

• 熔点：
  88-90 °C
• 沸点：
  263.35°C (rough estimate)
• 密度：
  0.9200 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  (4aR,8aS,9aR,10aS)-tetradecahydroanthracene 在 三氯化铝 作用下， 生成 十氫菲
  参考文献：
  名称：

  C HARACTERISTICS OF T WICE - TRANSFERRED , R URAL T RAUMA P ATIENTS

  摘要：

  Objective: Undertriage has seldom been evaluated in the trauma population. In rural states patients often go to the nearest hospital first, where they are evaluated and, if necessary, transferred to another hospital. If they are undertriaged when transferred to the second hospital, they will require a second transfer to a higher-level trauma center. Methods: The authors retrospectively reviewed the charts of all trauma patients at a level I trauma center from 1996 to 1999 who were seen at two acute care facilities because of a single acute traumatic event before reaching the trauma center. Ninety-three patient charts were analyzed. Results: Forty-six percent of the patients were victims of a motor vehicle crash. Patients were mostly transferred to the level I trauma center for non-spine orthopedic injuries (28%), followed by spine injuries (14%) and head injuries (13%). These patients were stable, as manifested by an average trauma score of 11.6. However, there was a significant positive interaction between injury severity score and time to definitive care. Conclusions: The authors infer from the data analysis that more serious or complex injuries took longer to evaluate. Since these patients were physiologically stable, reducing the number of twice-transferred trauma patients will involve refining transfer protocols concerning the need for specialty care.

  DOI：

  10.1080/10903120290938418
• 作为产物：
  描述：

  9,10-二氢蒽 在 三氯化铝 、 正己烷 、 溶剂黄146 、 铂 作用下， 生成 (4aR,8aS,9aR,10aS)-tetradecahydroanthracene
  参考文献：
  名称：

  76.氢蒽和对菲。第二部分

  摘要：

  DOI：

  10.1039/jr9440000286

文献信息

• Deep hydrogenation of coal tar over a Ni/ZSM-5 catalyst
  作者：Shi-Chao Qi、Lu Zhang、Xian-Yong Wei、Jun-ichiro Hayashi、Zhi-Min Zong、Lu-Lu Guo

  DOI：10.1039/c3ra47701k

  日期：——

  via the hydrogenation of 9,10-diphenylanthracene. Through hydrotreatment over the Ni/ZSM-5 catalyst, both high-temperature coal tar rich in condensed arenes and low-temperature coal tar mixing arenes with alkanes were greatly upgraded. The majority of arenes in the coal tars were deeply and even completely hydrogenated, which may open up a route for further processing and application of coal tar as

  我们已经开发了Ni / ZSM-5催化剂，并利用它在相对温和的条件下将包括萘，蒽和菲在内的一系列缩合芳烃完全加氢。十氢化萘，全氢蒽和全氢菲的收率分别达到100％，98.8％和25.8％。通过分析过氢芳烃的异构体分布，我们提出了双原子氢转移的机理，该机理进一步通过9,10-二苯基蒽的氢化。通过在Ni / ZSM-5催化剂上进行加氢处理，富含冷凝芳烃的高温煤焦油和带有烷烃的低温煤焦油混合芳烃都得到了大幅升级。煤焦油中的大多数芳烃都被深度甚至完全氢化，这可能为进一步处理和应用煤焦油作为清洁燃料开辟一条道路。
• Stereoselective hydrogenation reactions in chloroaluminate(III) ionic liquids: a new method for the reduction of aromatic compounds
  作者：Christopher J. Adams、Martyn J. Earle、Kenneth R. Seddon

  DOI：10.1039/a901302d

  日期：——

  Stereoselective hydrogenation reactions in the ionic liquid system 1-ethyl-3-methylimidazolium chloride–AlCl3 can be performed with excellent yields and selectivities, using electropositive metals and a proton source.

  在离子液体体系 1-乙基-3-甲基咪唑鎓氯化物-AlCl3 中，利用电阳性金属和质子源可以进行立体选择性氢化反应，并具有极佳的产率和选择性。
• Hydrogenation of Anthracene and Dehydrogenation of Perhydroanthracene on Pt/C Catalysts
  作者：A. N. Kalenchuk、A. E. Koklin、V. I. Bogdan、V. V. Lunin

  DOI：10.1134/s0036024418040106

  日期：2018.4

  The hydrogenation of anthracene on a heterogeneous catalyst containing 3 wt % Pt/C (Aldrich) at 215, 245, and 280°C and the pressures of 40 and 90 atm is studied. The hydrogenation of anthracene to a completely hydrogenated product is considered in detail. The final product (perhydroanthracene) consists of five conformational isomers with total selectivity of more than 99%. The ratio of perhydroanthracene

  研究了蒽在215、245和280°C以及40和90 atm的压力下在含3 wt％Pt / C（Aldrich）的非均相催化剂上的氢化反应。详细考虑了将蒽氢化成完全氢化的产物。最终产物（全氢蒽）由五个构象异构体组成，总选择性超过99％。最终产物中的全氢蒽异构体的比例由以下条件决定（P，T）的氢化。发现氢化速度随着苯环饱和度的增加而减慢。全氢蒽异构体的混合物在高压釜中于260-325°C于3 wt％Pt / C催化剂（Aldrich）上脱氢，并在流动反​​应器中于300-360°C在3 wt％Pt / Sibunit催化剂上脱氢。显示全氢蒽异构体在脱氢中的反应性不同。
• Prokopetz, Zhurnal Prikladnoi Khimii, 1938, vol. 11, p. 823,829, 831
  作者：Prokopetz

  DOI：——

  日期：——
• A MIODARONE AND R URAL E MERGENCY M EDICAL S ERVICES C ARDIAC A RREST P ATIENTS : A C OST A NALYSIS
  作者：Teresa E. Pazdral、John H. Burton、Tania D. Strout、Jay R. Bradshaw

  DOI：10.1080/10903120290938319

  日期：2002.1

  Objective: Recent American Heart Association guidelines suggest amiodarone as an antiarrhythmic in refractory ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT). The authors sought to assess the impact of amiodarone use on outcomes and cost associated with this practice in a rural emergency medical services (EMS) state. Methods: Statewide EMS records were reviewed for the calendar year 1999. Data reviewed included prehospital diagnosis, medications given by prehospital providers to patients with cardiac arrest, and procedures performed, including cardiopulmonary resuscitation (CPR) and defibrillation. Cost-benefit analysis assumed the cost of amiodarone treatment to be $137.65 per patient encounter. Absolute risk reduction (ARR) and number needed to treat (NNT) analysis utilized resuscitation rates published in the ARREST and ALIVE trials. Results: During the study period, EMS providers diagnosed 2,189 patients as having cardiac arrest. Five hundred thirty-five (24.4%) cardiac arrest patients were defibrillated. One hundred sixty patients (7.3%), including 15 who did not receive defibrillation, were given lidocaine during resuscitation efforts. The annual cost increase from current practice for a statewide amiodarone VF/VT protocol was $21,822.40 (10,572.87%). The initial cost to stock EMS vehicles for this protocol would be $50,115.52. The cost-benefit analysis yielded a potential for one additional patient survival to hospital discharge in Maine per 3.125 years of system-wide practice at a cost of $68,840.00. Conclusion: Based on current data, instituting amiodarone treatment for refractory VF and pulseless VT in a rural EMS setting requires the investment of substantial resources, relative to current treatment strategies, for any potential survival benefit.